Skip to main content
. 2021 Mar 11;13(3):904. doi: 10.3390/nu13030904

Figure 5.

Figure 5

Effect of chronic oral administration of Safr’InsideTM (6.25 mg/Kg) on anxiety-like behavior, measured in the LDT, and plasmatic corticosterone levels. (a) Latency to enter in the light box of the LDT; (b) Time in light box; (c) Locomotor activity as assessed by the distance covered (cm) normalized for the time spent in the light box; (d) Plasma corticosterone levels in ng/mL. LDT has been conducted after 3 weeks of treatment and 3 h after the gavage. Results are shown as mean ± SEM. Control (Water): n = 8; Safr’Inside: n = 9.